Genfit Pivots To Opposite End Of The Liver Disease Spectrum
Executive Summary
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
You may also be interested in...
Genfit/Ipsen’s PBC Data Leave Door Open For CymaBay
Genfit/Ipsen’s elafibranor and CymaBay’s seladelpar are vying to supplant Intercept’s Ocaliva in second-line primary biliary cholangitis, but elafibranor failed to hit a key differentiation endpoint in pruritus.
Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
Ipsen Gives Genfit Liver Drug New Lease Of Life
The French biotech was firmly on the ropes last year after elafibranor joined the long list of failures for NASH but the promise it has shown in primary biliary cholangitis has persuaded Ipsen to part with a hefty upfront fee.